EFFICACY OF BACTERIOPHAGE THERAPY AGAINST MULTIDRUG-RESISTANT KLEBSIELLA IN URINARY TRACT INFECTIONS: A SYSTEMATIC REVIEW.

Main Article Content

Hashir khan
Shahzad Hussain
Saqib Rasheed
Sardar Muhammad Abdullah
Yumna Bilal
Muhammad Daoud
Nabeel Hussain

Keywords

Bacteriophage therapy, urinary tract infections, multidrug-resistant Klebsiella, alternative treatment, antibiotic resistance, in vitro efficacy, systematic review.

Abstract

This systematic review evaluate the in vitro efficacy of bacteriophage therapy as an alternative treatment for urinary tract infections (UTIs) caused by multidrug-resistant Klebsiella species. With the increasing challenge of antibiotic resistance, alternative treatments such as phage therapy have gained attention due to their specificity and potential to reduce adverse effects associated with broad-spectrum antibiotics. Our review followed PRISMA guidelines and included studies from January 2021 onwards, sourced from databases such as PubMed, Scopus, Web of Science, and EMBASE. Five studies met our inclusion criteria and were analyzed to assess the effectiveness of phage therapy. The results indicate that phages exhibit variable lytic activities against Klebsiella strains, showing promise particularly in settings where traditional antibiotics fail. Factors influencing phage efficacy, such as phage-host specificity and environmental conditions, were also reviewed. The synthesis suggests a significant potential for phage therapy in clinical settings, though further research and standardized protocols are needed to fully harness its benefits against UTIs.

Abstract 173 | PDF Downloads 36

References

1. AL-ANANY, A. M., HOOEY, P. B., COOK, J. D., BURROWS, L. L., MARTYNIUK, J., HYNES, A. P. & GERMAN, G. J. 2023. Phage therapy in the management of urinary tract infections: a comprehensive systematic review. Phage, 4, 112-127.
2. BEHZADI, P., URBÁN, E., MATUZ, M., BENKŐ, R., GAJDÁCS, M. J. A. I. M., INFECTIOUS DISEASES & 15, P. H. V. 2021. The role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. 35-69.
3. BRONCANO-LAVADO, A., SANTAMARıA-CORRAL, G., ESTEBAN, J. & GARCıA-QUINTANILLA, M. Advances in bacteriophage therapy against relevant multidrug-resistant pathogens. Antibiotics (Basel). 2021; 10 (6): 672.
4. CIEŚLIK, M., BAGIŃSKA, N., GÓRSKI, A. & JOŃCZYK-MATYSIAK, E. 2021. Animal models in the evaluation of the effectiveness of phage therapy for infections caused by gram-negative bacteria from the ESKAPE group and the reliability of its use in humans. Microorganisms, 9, 206.
5. DÜZGÜNEŞ, N., SESSEVMEZ, M. & YILDIRIM, M. J. P. 2021. Bacteriophage therapy of bacterial infections: the rediscovered frontier. 14, 34.
6. FERNÁNDEZ, L., GUTIÉRREZ, D., GARCÍA, P. & RODRÍGUEZ, A. J. A. 2019. The perfect bacteriophage for therapeutic applications—a quick guide. 8, 126.
7. GUPTA, R. & SHARMA, S. J. I. J. O. M. R. 2022. Role of alternatives to antibiotics in mitigating the antimicrobial resistance crisis. 156, 464-477.
8. HIBSTU, Z., BELEW, H., AKELEW, Y., MENGIST, H. M. J. B. T. & THERAPY 2022. Phage therapy: a different approach to fight bacterial infections. 173-186.
9. LI, X., FAN, H., ZI, H., HU, H., LI, B., HUANG, J., LUO, P. & ZENG, X. J. J. O. C. M. 2022. Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019. 11, 2817.
10. PEIRANO, G., CHEN, L., KREISWIRTH, B. N., PITOUT, J. D. J. A. A. & CHEMOTHERAPY 2020. Emerging antimicrobial-resistant high-risk Klebsiella pneumoniae clones ST307 and ST147. 64, 10.1128/aac. 01148-20.
11. RĀCENIS, K. 2023. Antimicrobial Activity of Bacteriophages in Multidrug-Resistant and Biofilm Associated Infections. Summary of the Doctoral Thesis.
12. UYTTEBROEK, S., CHEN, B., ONSEA, J., RUYTHOOREN, F., DEBAVEYE, Y., DEVOLDER, D., SPRIET, I., DEPYPERE, M., WAGEMANS, J. & LAVIGNE, R. 2022. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. The Lancet Infectious Diseases, 22, e208-e220.
13. XU, Z.-Q., FLAVIN, M. T. & FLAVIN, J. J. E. O. O. I. D. 2014. Combating multidrug-resistant Gram-negative bacterial infections. 23, 163-182.
14. YANG, B., FANG, D., LV, Q., WANG, Z. & LIU, Y. J. F. I. P. 2021. Targeted therapeutic strategies in the battle against pathogenic bacteria. 12, 673239.
15. ZHANG, Y., LIN, Y., GALGANO, S., HOUDIJK, J., XIE, W., JIN, Y., LIN, J., SONG, W., FU, Y. & LI, X. J. A. 2022. Recent progress in phage therapy to modulate multidrug-resistant Acinetobacter baumannii, including in human and poultry. 11, 1406.

Most read articles by the same author(s)